Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma

Table 3

Distribution of ATAD2 and clinicopathological characteristics from TCGA LIHC patients.

Characteristics	No. of patients	ATAD2
		Low expression	High expression
Tissue
Tumor	374	216	158	33.670	<0.001
Nontumor	50	50	0
Gender
Male	234	129	105	0.478	0.560
Female	110	65	45
Age
<50	70	32	38	4.077	0.058
≥50	274	162	112
Race
Asian	155	72	83	11.843	0.008
American Indian	2	1	1
White	164	107	57
Black	14	9	5
Cirrhosis
Negative	179	105	74	0.896	0.370
Positive	146	78	68
Histological type
HCC	334	185	149	4.904	0.086
ICC	7	6	1
FL-HCC	3	3	0
Family cancer history
No	199	105	94	6.025	0.018
Yes	99	67	32
Grade
G1-G2	214	144	70	27.331	<0.001
G3-G4	130	50	80
Tumor status
Tumor free	222	124	98	0.004	1.000
With tumor	96	54	42
Vascular tumor cell type
None	194	118	76	2.650	0.109
Micro/macro	102	52	50
Stage
I-II	254	144	110	0.035	0.902
III-IV	90	50	40
T stage
T1-T2	258	147	111	0.142	0.709
T3-T4	86	47	39
N stage
N0	340	191	149	0.570	0.635
N1-N3	4	3	1
M stage
M0	339	190	149	1.150	0.392
M1	5	4	1

Abbreviations: HCC: hepatocellular carcinoma; ICC: hepatocholangiocarcinoma; FL-HCC: fibrolamellar carcinoma.